DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Adenoid Cystic Breast Carcinoma — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAdenoid Cystic Breast Carcinoma maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedDasatinibApproved drug
Structures already discussed alongside adenoid cystic breast carcinoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of EphA4 kinase domain — Dasatinib has a real, experimentally solved structure in complex with this target (PDB 2Y6O, 1.543 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 1n1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2Y6O · 1.543 Å · ligand Dasatinib (1N1). Experimental structure, not a prediction.
What the evidence adds up to
Adenoid cystic carcinoma of the breast is a rare malignancy, accounting for 0.1% to 1.0% of all breast cancers. It is classified as low-grade and has a favourable prognosis, with a low propensity for recurrence and metastasis. Despite being triple-negative by histology, its behaviour is unlike other triple-negative breast carcinomas. Complete surgical excision alone is curative in most circumstances in early-stage disease. Four retrospective studies have concluded that postoperative radiation contributes to improved survival, but there are no prospective or randomised data guiding treatment algorithms. Breast-conserving treatment including postoperative radiotherapy appears equivalent to mastectomy alone with respect to survival.
Routine axillary lymph node staging is not recommended because lymph node metastases are extremely rare. The value of adjuvant systemic therapies is not established. Late relapses can occur, so long-term follow-up is mandatory. A case report of a 32-year-old woman and a case report of a 79-year-old woman both describe management with lumpectomy and adjuvant radiation therapy. Early detection relies on diagnostic mammography and breast ultrasound.
The evidence base for this disease remains limited to retrospective studies and case reports. Prospective randomised studies are missing, and no specific recommendations for therapeutic management exist. The role of radiotherapy, while supported by retrospective data, has not been tested in a randomised trial. Patient stratification beyond early-stage versus late-stage disease is absent, and no funding for a prospective trial is evident in the published literature.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Clinical Oncology · 2025 · 2 citations
Adenoid Cystic Carcinoma of the Breast and Adjuvant Radiation Therapy
AbstractOBJECTIVES: Adenoid cystic carcinoma (ACC) of the breast is a rare special histologic type of breast cancer. This tumor is classified as low-grade and has a favorable prognosis, with rare occurrence of metastasis and distinctive characteristics. Due to the uncommon nature of this tumor, there are no specific recommendations regarding the therapeutic management of this malignancy. The aim of this review was to provide an overview of breast ACC clinical characteristics with a special focus on radiotherapy management. METHODS: A literature review was conducted up to January 2024 through a PubMed search using different combinations of pertinent keywords (eg, Adenoid cystic carcinoma alone, Adenoid cystic carcinoma AND breast Cancer AND radiotherapy; Adenoid cystic carcinoma AND breast cancer AND radiation therapy). RESULTS: This review highlighted the lack of prospective and randomized data guiding treatment algorithms for ACC. Four retrospective studies explored the impact of postoperative radiation and concluded that postoperative radiation contributes to improved survival. CONCLUSIONS: Thus, a consideration for radiotherapy indications in ACC of the breast could be further elucidated through prospective randomized studies.
Current Problems in Cancer Case Reports · 2024 · 1 citations · open access
Adenoid cystic carcinoma of the breast–A case report and review of the literature
AbstractAdenoid cystic carcinoma (ACC) is a rare type of breast cancer, and predominant adenoid cystic carcinomas are low grade and triple-negative by histology. Unlike other triple-negative breast carcinomas, ACC of the breast generally have a low propensity for recurrence and metastasis, with complete surgical excision alone being curative in most circumstances in early-stage disease. Here, we presents a case study detailing the clinical course of a 32-year-old female patient diagnosed with ACC of the breast. We emphasized the efficacy of standardized treatment protocols and highlighted recent advancements in research pertaining to this uncommon malignancy.
Klinische Monatsblätter für Augenheilkunde · 2010 · 1 citations
Adenoidzystisches Karzinom der Tränendrüse: Bericht von zwei Fällen und Literaturüberblick
AbstractThe adenoid cystic carcinoma of the lacrimal gland is a rare malignant orbital tumour, which has a generally poor prognosis. The therapy for adenoid cystic carcinoma of the lacrimal gland remains controversial. We present two cases of patients with adenoid cystic carcinoma of the lacrimal gland, who were treated with radical surgery in combination with radiotherapy. The therapeutic results are discussed with reference to relevant literature reports.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
Adjuvant radiation therapy for adenoid cystic carcinoma of the breast: A case report and literature review
AbstractAdenoid cystic carcinoma (ACC) of the breast is an uncommon malignancy, accounting for only 0.1% to 1.0% of all breast cancers. Unlike more aggressive breast carcinomas, ACC is characterized by slow progression and a favorable prognosis. Early detection relies heavily on diagnostic mammography and breast ultrasound. Standard treatment includes either lumpectomy followed by radiation therapy or mastectomy alone. Although rare, cases of late recurrence and metastasis have been documented, underscoring the need for long-term follow-up. This review explores the existing literature and presents the case of a 79-year-old woman diagnosed with adenoid cystic carcinoma of the left breast, managed with lumpectomy and adjuvant radiation therapy.
Cancer Genetics and Epigenetics · 2017 · 0 citations · open access
Current Status and Progress of Breast Adenoid Cystic Carcinoma
AbstractAdenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer. Despite its triple-negative status, this tumor has a very good prognosis. Breast-conserving treatment including postoperative radiotherapy seems to be equivalent to mastectomy alone with respect to survival. Routine axillary lymph node staging is not recommended since lymph node metastases are extremely rare. The value of adjuvant systemic therapies is not established. Late relapses can occur, so long-term follow-up is mandatory for these patients.
Clinical Cancer Investigation Journal · 2023 · 0 citations · open access
Adenoid Cystic Carcinoma of the Breast: A Case Report
AbstractAdenoid cystic carcinoma (ACC) is a basal-like subtype of mammary cribriform, solid, tubular, or trabecular architectural patterns. Epithelial and myoepithelial components make up the distinctive histologic pattern of ACC of the breast, which is like a well-known tumor with the same nomenclature that originates in the salivary gland. In this report, we describe a rare case of ACC in the breast cribriform, trabecular growth pattern. Here we present a rare case of breast adenoid cystic carcinoma w
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
AbstractAdenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC MSGT.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
